Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

The authors reply

Linder, Adam MD; Russell, James A. MD

doi: 10.1097/CCM.0000000000000809
Online Letters to the Editor
Buy

Centre for Heart Lung Innovation, Division of Critical Care Medicine, St. Paul’s Hospital, University of British Columbia, Vancouver, BC, Canada, and Division of Infection Medicine, Department of Clinical Sciences, Lund University, Lund, Sweden

Centre for Heart Lung Innovation, Division of Critical Care Medicine, St. Paul’s Hospital, University of British Columbia, Vancouver, BC, Canada

Dr. Russell served as a board member for Cyon Therapeutics; consulted for Cubist, Ferring, Leading Bioscience, La Jolla Pharmaceutical, and Grifols; has patents with PCSK9 in sepsis; and has stock in Cyon Therapeutics and Sirius Genomics. His institution received grant support from Ferring, AstraZeneca, and Sirius Genomics. Dr. Linder has disclosed that he does not have any potential conflicts of interest.

Copyright © by 2015 by the Society of Critical Care Medicine and Wolters Kluwer Health, Inc. All Rights Reserved.